Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The birth of @ISNeducation.
Desai T, Conjeevaram A, Taco O, Nair S, Sridharan S, Claure-Del Granado R, Neuen BL, Penmatsa KR, Basu G, Buchkremer F, Lopez-Almaraz E, Amare FA, Parada X, Vargas MC, Paunic Z, Iannuzzella F, Langote A, Madariaga H, Rodriguez Ramirez S, Bek SG, Orantes C, Chapagain A, Aggarwal G, Trivedi M, Sethi SK. Desai T, et al. Among authors: neuen bl. Kidney Int. 2017 Nov;92(5):1024-1028. doi: 10.1016/j.kint.2017.07.014. Kidney Int. 2017. PMID: 29055419 Free article. No abstract available.
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.
Sharma A, Marques P, Neuen BL, Fletcher RA, Slee A, Rapattoni W, Ang FG, Arnott C, Levin A, Verma S, Perkovic V, Mahaffey KW. Sharma A, et al. Among authors: neuen bl. Diabetes Obes Metab. 2024 Feb;26(2):758-762. doi: 10.1111/dom.15340. Epub 2023 Oct 26. Diabetes Obes Metab. 2024. PMID: 37881140 No abstract available.
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.
Fletcher RA, Arnott C, Rockenschaub P, Schutte AE, Carpenter L, Vaduganathan M, Agarwal R, Bakris G, Chang TI, Heerspink HJL, Jardine MJ, Mahaffey KW, Neal B, Pollock C, Jun M, Rodgers A, Perkovic V, Neuen BL. Fletcher RA, et al. Among authors: neuen bl. J Am Heart Assoc. 2023 Jul 4;12(13):e028516. doi: 10.1161/JAHA.122.028516. Epub 2023 Jun 22. J Am Heart Assoc. 2023. PMID: 37345834 Free PMC article.
Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD.
Collier W, Inker LA, Haaland B, Appel GB, Badve SV, Caravaca-Fontán F, Chalmers J, Floege J, Goicoechea M, Imai E, Jafar TH, Lewis JB, Li PKT, Locatelli F, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Heerspink HJL, Greene T; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)*. Collier W, et al. Among authors: neuen bl. Clin J Am Soc Nephrol. 2023 Feb 1;18(2):183-192. doi: 10.2215/CJN.0000000000000050. Epub 2023 Jan 19. Clin J Am Soc Nephrol. 2023. PMID: 36754007 Free PMC article.
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Nuffield Department of Population Health Renal Studies Group, et al. Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8. Epub 2022 Nov 6. Lancet. 2022. PMID: 36351458 Free PMC article.
National health policies and strategies for addressing chronic kidney disease: Data from the International Society of Nephrology Global Kidney Health Atlas.
Neuen BL, Bello AK, Levin A, Lunney M, Osman MA, Ye F, Ashuntantang GE, Bellorin-Font E, Gharbi MB, Davison S, Ghnaimat M, Harden P, Jha V, Kalantar-Zadeh K, Kerr PG, Klarenbach S, Kovesdy CP, Luyckx V, Ossareh S, Perl J, Rashid HU, Rondeau E, See EJ, Saad S, Sola L, Tchokhonelidze I, Tesar V, Tungsanga K, Kazancioglu RT, Wang AY, Yang CW, Zemchenkov A, Zhao MH, Jager KJ, Caskey FJ, Perkovic V, Jindal KK, Okpechi IG, Tonelli M, Feehally J, Harris DC, Johnson DW. Neuen BL, et al. PLOS Glob Public Health. 2023 Feb 1;3(2):e0001467. doi: 10.1371/journal.pgph.0001467. eCollection 2023. PLOS Glob Public Health. 2023. PMID: 36963092 Free PMC article.
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.
Yi TW, Wong MMY, Neuen BL, Arnott C, Poirier P, Seufert J, Slee A, Rapattoni W, Ang FG, Wheeler DC, Mahaffey KW, Perkovic V, Levin A. Yi TW, et al. Among authors: neuen bl. Diabetes Obes Metab. 2023 Jul;25(7):2043-2047. doi: 10.1111/dom.15065. Epub 2023 Apr 24. Diabetes Obes Metab. 2023. PMID: 36974373 No abstract available.
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
Tsoukas MA, Woo V, Tobe SW, Slee A, Rapattoni W, Ang FG, Seufert J, Neuen BL, Arnott C, Mahaffey KW, Wheeler DC. Tsoukas MA, et al. Among authors: neuen bl. Diabetes Obes Metab. 2023 Jul;25(7):2038-2042. doi: 10.1111/dom.15057. Epub 2023 Apr 4. Diabetes Obes Metab. 2023. PMID: 36942888 No abstract available.
114 results